AbbVie, Teva Pay-For-Delay Deal Draws More Antitrust Claims

Law360, New York (May 8, 2013, 3:54 PM EDT) -- AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were sued Tuesday in Pennsylvania federal court over a patent settlement that allegedly delayed market entry of a generic form of AbbVie's Niaspan cholesterol drug, the latest of several putative antitrust class actions against the companies.

A New York hotel workers union benefits plan lodged a proposed class action challenging a so-called pay-for-delay deal that resolved a patent dispute between two of the drug companies' predecessors. The suit — filed by named plaintiff New York Hotel Trades Council and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.